June 23, 2026
Shenzhen, China – June 16, 2026 – The launch ceremony of the 2026 AI Brain-Computer Interface (BCI) Global Challenge and NeuroHub Accelerator took place at the Shenzhen Brain Science and Technology Industry Innovation Center.
June 1, 2026
SHENZHEN, China – May 29, 2026 – Blue Ocean Capital officially celebrated the relocation of its headquarters to Guangming Science City today, hosting a landmark event that integrated cutting-edge brain science with contemporary art.
May 25, 2026
The 25th Greater China Private Equity Summit concluded successfully in Hong Kong on May 19, bringing together over 650 participants, with more than 60 speakers exploring industry trends and emerging opportunities across the region.Frank Yang, Founding Partner and CEO of Blue Ocean Capital Group (“BOCG”), chaired the biotech roundtable, where leading global investment experts engaged in in-depth discussions on cutting-edge biotech developments and cross-border investment strategies.
April 30, 2026
Blue Ocean Capital Group (BOCG) today announced that, as part of its strategy to further deepen its footprint and sharpen its focus in the life sciences sector, its Shenzhen headquarters and affiliated incubation platform Youjoy Incubator will officially relocate Guangming Technology Finance Towerin in Guangming Science City, effective May 1, 2026.This move represents a critical shift of BOCG’s strategic move toward the source of innovation. By embedding itself into one of the world’s leading hubs for life sicence R&D, BOCG aims to strengthen its early-stage enabling capabilities and value-creation partnerships at the forefront of life sciences.
January 14, 2026
HONG KONG, January 9, 2026 – Ribo LifeScience Co., Ltd. (“Ribo LifeScience” or the “Company,” Stock Code: 06938.HK), a leading company in small interfering RNA (siRNA) therapeutics and a multi-round investments portfolio company of Blue Ocean Capital Group (“BOCG”), has officially listed on the Main Board of the Hong Kong Stock Exchange. The Company successfully raised approximately HK$1.83 billion (after exercising the offer size adjustment option), marking the second-largest IPO in the 18A biotech sector since 2022 and the first IPO for Blue Ocean Capital in 2026.
January 12, 2026
SHENZHEN, December 2025 – During the Fifth Frontiers of Brain Science and Industry Conference and the 2025 Shenzhen Brain-Computer Interface Expo, Blue Ocean Capital officially announced the establishment of its RMB 160 million (US$23 million) Brain Science Seed Fund. This specialized fund is designed to accelerate the transformation of breakthrough research into market-ready solutions, focusing on the most promising frontiers of life science technologies.
August 12, 2025
Recently, Boan Biotech, a portfolio company of Blue Ocean Capital, announced that its independently developed Boyouping® (Dulaglutide Injection) has been granted marketing approval by the National Medical Products Administration for blood glucose control in adult patients with type 2 diabetes. Boyouping is the world’s first approved dulaglutide biosimilar, showcasing Boan Biotech’s strong R&D capabilities. Congratulations to Boan Biotech!
April 15, 2025
BOCG's portfolio company, HighTide Therapeutics, today announced that two Phase 3 trials of berberine ursodeoxycholate (HTD1801) in Chinese patients with type 2 diabetes mellitus (T2DM) met their primary endpoints and gated secondary endpoints. HighTide plans to submit a new drug application for HTD1801 as a treatment for T2DM to the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) later this year.Congratulations toHighTide Therapeutics on achieving another important milestone in the clinical development of HTD1801. Looking forward to HighTide Therapeutics bringing safer and more effective treatment options to the large population of type 2 diabetes patients!
